Bardoxolone methyl was previously being investigated by Reata Pharmaceuticals, Inc. in partnership with Abbott Laboratories and Kyowa Hakko Kirin, as an experimental therapy for advanced chronic kidney disease (CKD) in type 2 diabetes mellitus patients.
methyl salicylate | Methyl-CpG-binding domain | Poly (methyl methacrylate) | Methyl tert-butyl ether | Methyl Salicylate | Methyl salicylate | Methyl red | Methyl diethanolamine | Methyl caffeate | methyl | 4-Methyl-2-pentanol |